#### 2018 CAG NEEDS ASSESSMENT SURVEY

#### **Quick Overview: Educational Topic Findings**

The online 2018 Needs Assessment survey was programmed through SurveyMonkey and a personalized request to complete the questionnaire was emailed to CAG members on March 15<sup>th</sup> and again on March 22<sup>nd</sup>. As of April 1, 2018 a total of 248 respondents had completed the survey demographics, of which **236** went on to rate potential educational topics. For potential educational topics respondents were asked to indicate their level of interest for **46** topics on a five-point scale ranging from 'No interest' to 'Very interested'.


Respondents	1 <sup>st</sup> Choice	2 <sup>nd</sup> Choice	3 <sup>rd</sup> Choice	4 <sup>th</sup> Choice	5 <sup>th</sup> Choice
Gastroenterologists - Adult (n=130)	(% very interested) Endoscopic techniques & therapeutics: management (polypectomy (51.5%)	(% very interested) Crohn's & Ulcerative Colitis: Therapeutics, Tx of complications, fistulas etc; (47.7%)	(% very interested) Hands-on stations for endoscopic skills (39.2%)	(% very interested) IBD: Pathogenesis, genetics, etiology; Alternative approaches to management (e.g. cannabis) (each topic 30.0%)	(% very interested) Pancreatitis & pancreatic diseases (29.2%)
Gastroenterologists - Pediatric (n=19)	Pediatric Liver Diseases (57.9%)	Crohn's & Ulcerative Colitis: Therapeutics, Tx of complications, fistulas, etc. (47.4%)	Celiac Disease: Dx, management, complications, new therapies; Malabsorption: Dx & management; IBD: Pathogenesis, genetics, etiology (each topic 42.1%)	Dyspepsia & upper GI functional disorders (36.8%)	Esophageal & upper GI motility disorders; Chronic diarrhea: Dx & management; Nutrition: assessment in specific disease states; Nutrition: management; Hands-on stations for endoscopic skills; Endoscopic techniques & therapeutics: management (polypectomy) (each topic 31.6%)
Teaching hospital based (n=146)	Crohn's & Ulcerative Colitis: therapeutics, Tx of complications, fistulas etc; (46.6%)	Endoscopic techniques & therapeutics: management (polypectomy) (41.8%)	IBD: Pathogenesis, genetics, etiology (38.4%)	Hands-on stations for endoscopic skills (34.9%)	Pancreatitis & pancreatic diseases (28.8%)
Community hospital based (n=51)	Crohn's & Ulcerative Colitis: therapeutics, Tx of complications, fistulas etc; Endoscopic techniques & therapeutics: management (polypectomy) (each 52.9%)	Hands-on stations for endoscopic skills (43.1%)	NAFLD; Chronic diarrhea: Dx & management (each topic 39.2%)	Celiac disease: Dx, management, complications, new therapies; IBD: Pathogenesis, genetics, etiology (each topic 37.2%)	Diseases of the gallbladder & biliary tract (33.3%)
Basic Scientist (n=49)	IBD: Pathogenesis, genetics, etiology (53.1%)	Crohn's & Ulcerative Colitis: Therapeutics, Tx of complications, fistulas etc. (36.7%)	<b>GI Oncology;</b> (26.5%)	Lower functional bowel disorders (IBS); Approach to GI infections (C.difficile & other pathogens) (each 24.5%)	<b>Celiac disease:</b> Dx, management, complications, new therapies (20.4%)
Trainees (n=30)	Hands-on stations for endoscopic skills; Endoscopic techniques & therapeutics: management (polypectomy) (each 60.0%)	Crohn's & Ulcerative Colitis: Therapeutics, Tx of complications,fistulas, etc. (56.7%)	Endoscopy: EUS (53.3%)	Endoscopy: ERCP; Endoscopy: Advanced modalities (e.g. double balloon, PDT etc.) (each topic 50.0%)	IBD: Pathogenesis, genetics, etiology (46.7%)

The table below summarizes the top picks (percent that selected 'Very interested') for the major respondent subgroups

Canadian Association L'Association Canadienne

## Q3 Specialty

Answered: 249 Skipped: 0




ANSWER CHOICES	RESPONSES
Gastroenterologist (adult)	<b>55.42%</b> 13
Gastroenterologist (pediatrics)	<b>7.63%</b> 1
Hepatologist	<b>4.02%</b> 1
Surgeon	2.81%
Clinical Scientist	<b>6.43%</b> 1
Basic Scientist	<b>20.08%</b> 5
Resident/Trainee	<b>12.45%</b> 3
Other	<b>6.02%</b> 1
Total Respondents: 249	



## Q4 Your location:

Answered: 249 Skipped: 0




ANSWER CHOICES	RESPONSES	
BC	10.44%	26
AB	18.47%	46
SK	1.61%	4
MB	4.02%	10
ON	42.57%	106
QC	10.44%	26
NB	2.01%	5
NS	2.81%	7
PE	0.40%	1
NL	3.21%	8
NWT/Nunavut/Yukon	0.00%	0
Outside Canada	4.02%	10
TOTAL		249



#### **Q5** Affiliation

Answered: 248 Skipped: 1




ANSWER CHOICES	RESPONSES	
Predominantly teaching hospital based	61.29%	152
Predominantly community-based with hospital privileges	20.97%	52
Predominantly community-based without hospital privileges	3.23%	8
None of the above/not applicable	14.52%	36
TOTAL		248



## Q6 Education (check all that apply)


Answered: 248 Skipped: 1



ANSWER CHOICES	RESPONSES	
MD or equivalent	74.60%	185
PhD	25.40%	63
Masters Degree	25.81%	64
Bachelors Degree	25.81%	64
Other	4.03%	10


Total Respondents: 248





ANSWER CHOICES	RESPONSES	
Male	70.97%	176
Female	29.03%	72
TOTAL		248






## Q8 Year of medical school graduation

ANSWER CHOICES	RESPONSES	
Before 1980	13.31%	33
1980-1989	14.92%	37
1990-1999	13.31%	33
2000-2009	25.40%	63
2010-2015	9.27%	23
>2015	2.42%	6
Not applicable	21.37%	53
TOTAL		248





### Q9 In which category do you spend most of your time? (check only one)


ANSWER CHOICES	RESPONSES	
Clinical Practice	53.23%	132
Basic Research (>50%)	22.18%	55
Clinical Research (>50%)	6.85%	17
Teaching (>50%)	1.61%	4
Administration (>50%)	1.21%	3
Clinician Researcher (research <=50%)	7.26%	18
Clinician Teacher (teaching <=50%)	5.24%	13
Other	2.42%	6
TOTAL		248




#### Q10 Please indicate how strongly you would like to see an educational event on each topic listed below:

Answered: 236 Skipped: 13


Summary of only those educational event topics rated VERY INTERESTED - for all ratings see pages 13,14)



The 11 HIGHEST rated topics (above)







#### **Topics in which 6-18% were VERY INTERESTED**

\*Please note: The liver related topics were answered by majority of CAG luminal respondents



#### Q12 Optional: List one or two OTHER topics that you would like to see covered. Please DO NOT repeat topics listed above

Answered: 85 Skipped: 164


(For the COMPLETE alphabetical list of ALL OTHER suggested topics please see APPENDIX A)

Summary of suggestions for topics that address CanMEDS roles other than Medical Expert:

- 360 Evaluation
- Access to care
- Advice for residents interested in starting a research career
- Approach to functional disorders, ie pyschological support
- Billing efficiency
- CAG approved standardized informed consent for endoscopic procedures:what MUST be said and documented
- Cognitive behavioural therapy in gastroenterology
- Competence by Design
- Doctor wellbeing and health
- Ending a physician-patient relationship
- Ethics/Integrity of practice: doing procedures for money and very little else. How can we control this?
- Feedback
- Health services utilization
- How to educate referring physicians who send their patients for QUICK scopes before they refer to you for a clinical answer
- Legal responsibilities dealing with difficult patients
- Physician burnout
- Physicians with disabilities (burnout, damage/pain from doing procedures, where and who to give support and options without a union to support us, etc
- Politicians why they put down health care and MDs
- Teaching endoscopy
- Technology in patient management and communication
- Time management




#### Q11 For the content of a **BASIC SCIENCE** educational session, please indicate how strongly you would like to see each topic below addressed




(Sorted by highest rating of Very interested from left to right)

#### Q13 Please indicate all CAG continuing professional development (CPD) programs/tools/events that you have used/participated in over the past year




(n= number of respondents for each program/tool/event)






(n= number of respondents who participated and chose to answer this question regarding each program/tool/event. Reponse was not mandatory.)



(n= number of respondents who participated and chose to answer this question regarding each program/tool/event. Reponse was not mandatory.)



#### Q 14. Using the 5-point scale please answer each of the following questions



Answered: 227 Skipped

# Q 10. Please indicate how strongly you would like to see an educational event on each topic listed below

Answered: 236 Skipped: 13

Listed from greatest percentage "Very Interested" to least percentage "Very Interested"


ISLEU I	ioni greatest percentage very interested	to least percer	naye very nnere	53100		
		No interest	Minor interest	Neutral/not sure	Some interest	Very interested
1.	Crohn's & Ulcerative Colitis: Therapeutics, Tx of complications,fistulas, etc.	5.08%	8.05%	11.02%	30.08%	45.76%
2.	Endoscopic techniques & therapeutics: management (polypectomy)	17.80%	5.51%	10.59%	25.42%	40.68%
3.	IBD: Pathogenesis, genetics, etiology	5.93%	11.86%	17.37%	27.54%	37.29%
4.	Hands-on stations for endoscopic skills	19.49%	8.90%	12.71%	25.00%	33.90%
5.	Celiac disease; Dx, management, complications, new therapies	6.78%	8.47%	13.98%	43.64%	27.12%
6.	Chronic diarrhea: Dx & management	10.17%	10.59%	15.68%	36.86%	26.69%
7.	NAFLD	16.95%	13.56%	18.22%	25.42%	25.85%
8. 9.	Lower functional bowel disorders (IBS) Radiological Imaging modalities for GI	9.32%	8.47%	14.41%	43.22%	24.58%
	disorders	12.29%	12.71%	13.56%	36.86%	24.58%
10	. Pancreatitis & pancreatic diseases	11.02%	16.10%	15.25%	33.90%	23.73%



11. Alternative approaches to management (e.g. cannabis)   11.86%   19.07%   17.80%   29.24%   22.03%     12. GI Oncology   11.86%   19.07%   17.80%   29.24%   22.03%     13. Dyspepsiol & upper GI functional disorders   14.83%   19.07%   17.37%   27.12%   21.61%     14. Diseases of the galbladder & biliary tract   14.83%   19.07%   17.37%   27.12%   21.61%     15. Anortectal disease   15.95%   17.80%   11.02%   33.05%   21.19%     16. Nutrition: assessment in specific disease states   9.75%   10.59%   17.80%   42.37%   20.76%     18. Nutrition: management   11.86%   12.71%   15.65%   39.41%   20.34%     19. Upper GI bededing   13.66%   12.71%   15.65%   39.41%   20.34%     21. Approach to GI infections (C. difficite & other pathogens)   0.55%   8.90%   21.19%   19.92%     22. Endoscopy: ERCP   34.75%   16.85%   18.22%   10.59%   19.07%     22. Non-reflux esophagits, etc.)   11.44%   16.95%   32.19%   19.92%     24. Obesity   0.59%   19.07%   1			No interest	Minor interest	Neutral/not sure	Some interest	Very interested
13. Dyspepsia & upper GI functional disorders   14.83%   14.41%   16.53%   32.63%   21.61%     14. Diseases of the gallbladder & biliary tract   14.83%   19.07%   17.37%   27.12%   21.61%     15. Ancrectal disease   16.95%   17.80%   11.02%   33.05%   21.19%     16. NUtrition: assessment in specific disease states   9.75%   10.59%   18.22%   40.25%   21.19%     17. Non-IBD intestinal disorders (microscopic colitis, etc.)   7.20%   11.86%   17.80%   42.37%   20.76%     18. Nutrition: management   11.86%   12.71%   16.95%   36.86%   19.92%     20. Malabsorption: Dx & management   11.86%   14.41%   11.44%   41.95%   19.92%     21. Approach to Gl infections (C. difficile & alsofw   8.05%   8.90%   21.19%   19.92%     22. Endoscopy: ERCP   34.75%   16.95%   18.22%   10.59%   19.49%     24. Obesity   10.17%   17.37%   22.03%   17.37%     25. Non-reflux esophagetal disorders (c.g. disorders (c.g. disorders)   11.44%   16.53%   22.89%   16.55%     28. Personal health   23.73% <t< td=""><td></td><td>management (e.g. cannabis)</td><td>11.86%</td><td></td><td>19.07%</td><td></td><td>23.31%</td></t<>		management (e.g. cannabis)	11.86%		19.07%		23.31%
14. Diseases of the galibladder & billary tract   14.83%   19.07%   17.37%   27.12%   21.61%     15. Anorectal disease   16.95%   17.80%   11.02%   33.05%   21.19%     16. Nutrition: assessment in specific disease states   9.75%   10.59%   18.22%   40.25%   21.19%     17. Non-IBD intestinal disorders (microscopic collits, etc.)   7.20%   11.86%   17.80%   42.37%   20.76%     18. Nutrition: management   11.86%   12.71%   16.95%   36.86%   19.92%     20. Malabsorption: Dx & management   11.86%   14.41%   11.44%   42.37%   19.92%     21. Approach to GI infections (C. difficile & other pathogens)   8.05%   8.90%   21.19%   41.95%   19.92%     23. Esophageal & upper GI motility disorders   10.59%   19.07%   12.71%   38.56%   19.07%     24. Obserity   10.17%   17.37%   22.03%   32.20%   18.22%     24. Obserity   10.17%   17.37%   22.03%   17.37%     25. Non-reflux esophaguis, etc.)   25.00%   17.80%   17.80%   22.03%   16.53%     28. Personal health   23.73% <td></td> <td></td> <td>11.86%</td> <td>19.07%</td> <td>17.80%</td> <td>29.24%</td> <td>22.03%</td>			11.86%	19.07%	17.80%	29.24%	22.03%
15. Anorectal disease   16.95%   17.80%   11.02%   33.05%   21.19%     16. Nutrition: assessment in specific diseases states   9.75%   10.59%   18.22%   40.25%   21.19%     17. Non-IBD intestinal disorders (microscopic collis, etc.)   7.20%   11.86%   17.80%   42.37%   20.76%     18. Nutrition: management   11.86%   12.71%   15.68%   39.41%   20.34%     19. Upper GI bleeding   13.56%   12.71%   16.95%   36.86%   19.92%     20. Malabsorption: Dx & management   11.86%   14.41%   11.44%   42.37%   19.92%     21. Approach to GI infections (C. difficile & other pathogens)   34.75%   16.95%   18.22%   10.59%   19.92%     23. Esophageal & upper GI motility disorders   34.75%   16.95%   18.22%   10.69%   19.07%     24. Obesity   10.17%   17.37%   22.03%   32.20%   18.22%     25. Non-refux esophagatis, etc.)   11.44%   16.95%   15.68%   38.14%   17.80%     25. Other full esophaguts   20.76%   16.53%   19.49%   27.54%   16.53%     26. Endoscopy: cdyanced modaltites	14.		14.83%				
16.   Nurritor: assessment in specific disease states   9.75%   10.59%   18.22%   40.25%   21.19%     17.   Non-IBD intestinal disorders (microscopic colitis, etc.)   7.20%   11.86%   17.80%   42.37%   20.76%     18.   Nutrition: management   11.86%   12.71%   15.68%   39.41%   20.34%     19.   Upper GI bleeding   13.56%   12.71%   16.95%   36.66%   19.92%     20.   Malabsorption: Dx & management   11.86%   14.41%   11.44%   42.37%   19.92%     21.   Approach to GI infections (C. difficile & other pathogens)   84.75%   16.55%   18.22%   10.59%   19.49%     23.   Esophageal & upper GI motility disorders   10.59%   19.07%   12.71%   38.56%   19.07%     24.   Obesity   10.17%   17.37%   22.03%   32.20%   18.22%     25.   Non-reflux esophogeal disorders (cosinophilic esophagits, etc.)   11.44%   16.53%   12.68%   17.80%   17.80%   17.80%   22.03%   16.53%     26.   Personal health   23.73%   17.37%   20.34%   22.03% <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>							
disease states     9.75%     10.59%     18.22%     40.25%     21.19%       17. Non-IBD intestinal disorders (microscopic collis, etc.)     7.20%     11.86%     17.80%     42.37%     20.76%       18. Nutrition: management     11.86%     12.71%     15.68%     39.41%     20.34%       19. Upper GI bleeding     13.56%     12.71%     16.95%     38.68%     19.92%       20. Malabsorption: Dx & management     11.86%     12.71%     16.95%     38.68%     19.92%       21. Approach to GI infections (C. difficile & other pathogens)     8.05%     8.90%     21.19%     41.95%     19.22%       22. Endoscopy: ERCP     34.75%     16.95%     18.22%     10.59%     19.07%     12.71%     38.56%     19.07%       24. Obesity     10.17%     17.37%     22.03%     32.20%     18.22%       25. Non-reflux esophogeal disorders (cosinophilic esophaguitis, etc.)     11.44%     16.55%     15.68%     38.14%     17.80%       26. Endoscopy: Advanced modalities (e.g. double balloon, PDT, etc.)     25.00%     17.80%     21.19%     21.19%     25.6%     16.53%			16.95%	17.80%	11.02%	33.05%	21.19%
(microscopic colitis, etc.)     7.20%     11.86%     17.80%     42.37%     20.76%       18. Nutrition: management     11.86%     12.71%     15.68%     39.41%     20.34%       19. Upper Gl bleeding     13.56%     12.71%     16.95%     36.86%     19.92%       20. Malabsorption: Dx & management     11.86%     12.71%     16.95%     36.86%     19.92%       21. Approach to Gl infections (C. difficile & other pathogens)     8.05%     8.90%     21.19%     41.95%     19.92%       22. Endoscopy: ERCP     34.75%     16.95%     18.22%     10.59%     19.07%       24. Obesity     10.17%     17.37%     22.03%     32.20%     18.22%       25. Non-reflux esophogeal disorders (cosinophilic esophagitis, etc.)     11.44%     16.95%     15.66%     38.14%     17.80%       26. Endoscopy: Advanced modalities (e.g. dobleadinon, Plet.)     29.24%     17.80%     22.03%     16.55%       29. Autoimmune liver diseases     20.76%     16.53%     19.49%     27.54%     15.68%       30. Endoscopy: Capsule     24.58%     17.80%     21.19%     20.76%	10.	•	9.75%	10.59%	18.22%	40.25%	21.19%
18. Nutrition: management   11.86%   12.71%   15.68%   39.41%   20.34%     19. Upper GI bleeding   13.66%   12.71%   16.95%   36.86%   19.92%     20. Malabsorption: Dx & management   11.86%   14.41%   11.44%   42.37%   19.92%     21. Approach to GI infections (C. difficile & other pathogens)   8.05%   8.90%   21.19%   41.95%   19.92%     22. Endoscopy: ERCP   34.75%   16.95%   18.22%   10.59%   19.07%     23. Esophageal & upper GI motility disorders (cosinophilic esophagitis, etc.)   10.17%   17.37%   22.03%   32.20%   18.22%     25. Non-reflux esophogeal disorders (cosinophilic esophagitis, etc.)   11.44%   16.95%   17.80%   17.80%   22.03%   17.37%     26. Endoscopy: Advanced modalities (e.g. double balloon, PDT, etc.)   25.00%   17.80%   17.80%   22.03%   16.53%     28. Personal health   29.24%   14.41%   16.53%   29.84%   16.65%     30. Endoscopy: Capsule   24.58%   17.80%   21.19%   21.95%   16.68%     33. Faching theory & techniques   19.07%   21.19%   23.31%   30.51%	17.		7 200/	11.969/	17 000/	40.070/	20.760/
19. Upper Gl bleeding   13.56%   12.71%   16.95%   36.86%   19.92%     20. Malabsorption: Dx & management   11.86%   14.41%   11.44%   42.37%   19.92%     21. Approach to Gl infections (C. difficile & other pathogens)   8.05%   8.90%   21.19%   41.95%   19.92%     22. Endoscopy: ERCP   8.475%   16.95%   18.22%   10.59%   19.49%     23. Esophageal & upper Gl motility disorders (cosinophilic esophagitis, etc.)   10.17%   17.37%   22.03%   32.20%   18.22%     25. Non-reflux esophogeal disorders (cosinophilic esophagitis, etc.)   11.44%   16.95%   17.80%   22.03%   17.37%     26. Endoscopy: Advanced modalities (e.g. double balloon, PDT, etc.)   25.00%   17.80%   17.80%   22.03%   16.53%     28. Personal health   23.73%   17.37%   20.34%   20.36%   16.53%     29. Autoimmune liver diseases   20.76%   16.53%   19.49%   17.56%   15.68%     30. Endoscopy: Capsule   24.58%   17.80%   21.19%   20.76%   16.53%     31. Barrett's esophagues   19.07%   21.19%   23.73%   14.83%     32	10	· · · /					
20. Malabsorption: Dx & management   11.86%   14.41%   11.44%   42.37%   19.92%     21. Approach to GI infections (C. difficile & other pathogens)   8.05%   8.90%   21.19%   41.95%   19.92%     22. Endoscopy: ERCP   34.75%   16.95%   18.22%   10.59%   19.49%     24. Obesity   10.17%   17.37%   22.03%   32.20%   18.22%     25. Non-reflux esophogeal disorders (eosinophilic esophagitis, etc.)   11.44%   16.95%   15.68%   38.14%   17.80%     26. Endoscopy: Advanced modalities (e.g. double balloon, PDT, etc.)   25.00%   17.80%   17.80%   22.03%   16.55%     28. Personal health   23.73%   17.37%   20.34%   16.53%   28.8%   16.65%     30. Endoscopy: Capsule   24.58%   17.80%   21.19%   20.76%   15.68%     31. Barrett's esophagus   13.56%   17.80%   21.19%   20.76%   15.68%     32. Endoscopy: Cupsule   24.58%   17.80%   21.19%   20.76%   15.68%     32. Endoscopy: EUS   35.59%   18.22%   19.49%   11.86%   14.83%     33. Teaching theory & techniques <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td>		-					
21. Approach to Gl infections (C. difficile & other pathogens)   8.05%   8.90%   21.19%   41.95%   19.92%     22. Endoscopy: ERCP   34.75%   16.95%   18.22%   10.59%   19.49%     24. Obesity   10.59%   19.07%   12.71%   38.56%   19.07%     24. Obesity   10.17%   17.37%   22.03%   32.20%   18.22%     25. Non-reflux esophagitis, etc.)   11.44%   16.95%   15.68%   38.14%   17.80%     26. Endoscopy: Advanced modalities (e.g. double balloon, PDT, etc.)   25.00%   17.80%   22.03%   17.37%     27. Financial planning, retirement, incorporation   29.24%   14.41%   16.53%   22.88%   16.53%     28. Personal health   23.73%   17.37%   20.34%   22.03%   15.68%     30. Endoscopy: EUS   35.59%   18.22%   19.49%   14.83%     33. Teaching theory & techniques   19.07%   21.19%   23.73%   14.83%     34. Portal HTN and cirrhosis   20.34%   15.25%   17.00%   32.20%   14.41%     35.66%   18.19%   13.56%   17.80%   22.03%   13.56% <tr< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr<>							
other pathogens)     8.05%     8.90%     21.19%     41.95%     19.92%       22. Endoscopy: ERCP     34.75%     16.95%     18.22%     10.59%     19.49%       23. Esophageal & upper GI motility disorders     10.59%     19.07%     12.71%     38.56%     19.07%       24. Obesity     10.17%     17.37%     22.03%     32.20%     18.22%       25. Non-reflux esophageal disorders (cosinophilic esophagitis, etc.)     11.44%     16.95%     17.80%     22.03%     17.37%       26. Endoscopy: Advanced modalities (e.g. double balloon, PDT, etc.)     25.00%     17.80%     17.80%     22.03%     16.53%       27. Financial planning, retirement, incorporation     29.24%     14.41%     16.53%     22.88%     16.95%       28. Personal health     23.73%     17.37%     20.34%     22.03%     15.68%       30. Endoscopy: Capsule     24.58%     17.80%     21.19%     20.76%     15.68%       31. Barrett's esophagus     13.56%     17.80%     21.19%     20.76%     15.68%       33. Teaching theory & techniques     19.07%     12.19%     21.19%			11.00%	14.41%	11.44%	42.37%	19.92%
22. Endoscopy: ERCP   34.75%   16.95%   18.22%   10.59%   19.49%     23. Esophageal & upper GI motility disorders   10.59%   19.07%   12.71%   38.56%   19.07%     24. Obesity   10.17%   17.37%   22.03%   32.20%   18.22%     25. Non-reflux esophogeal disorders (eosinophilic esophagitis, etc.)   11.44%   16.95%   15.68%   38.14%   17.80%     26. Endoscopy: Advanced modalities (e.g. double bailoon, PDT, etc.)   25.00%   17.80%   22.03%   16.53%     27. Financial planning, retirement, incorporation   29.24%   14.41%   16.53%   22.88%   16.95%     28. Personal health   23.73%   17.37%   20.34%   22.03%   15.68%     30. Endoscopy: Capsule   24.58%   17.80%   21.19%   20.76%   15.68%     31. Barrett's esophagus   35.59%   18.22%   19.49%   14.83%     32. Endoscopy: EUS   35.59%   18.22%   19.49%   14.83%     33. Teaching theory & techniques   19.07%   21.19%   23.73%   14.83%     34. Portal HTN and cirrhosis   20.34%   15.25%   17.80%   32.20%   14.4	21.		8 05%	8 00%	21 10%	/1 05%	10 02%
23. Esophageal & upper GI motility disorders     10.59%     19.07%     12.71%     38.56%     19.07%       24. Obesity     10.17%     17.37%     22.03%     32.20%     18.22%       25. Non-reflux esophogeal disorders (eosinophilic esophagitis, etc.)     11.44%     16.95%     15.68%     38.14%     17.80%       26. Endoscopy: Advanced modalities (e.g. double balloon, PDT, etc.)     25.00%     17.80%     17.80%     22.03%     16.53%       28. Personal health     23.73%     17.37%     20.34%     22.03%     16.53%       29. Autoimmune liver diseases     20.76%     16.53%     19.49%     27.54%     15.68%       30. Endoscopy: Capsule     24.58%     17.80%     23.31%     30.51%     14.83%       32. Endoscopy: Capsule     35.59%     18.22%     19.49%     11.86%     14.83%       33. Teaching theory & techniques     19.07%     21.19%     23.31%     30.51%     14.83%       34. Portal HTN and cirrhosis     20.34%     15.25%     17.80%     22.03%     14.41%       35. Ufcer disease/Helicobacter/NSAIDs     13.56%     21.19%     21.61% </td <td>22</td> <td>, ,</td> <td></td> <td></td> <td></td> <td></td> <td></td>	22	, ,					
disorders     10.59%     19.07%     12.71%     38.56%     19.07%       24. Obesity     10.17%     17.37%     22.03%     32.20%     18.22%       25. Non-reflux esophagela disorders (eosinophilic esophagitis, etc.)     11.44%     16.95%     15.68%     38.14%     17.80%       26. Endoscopy: Advanced modalities (e.g. double balloon, PDT, etc.)     25.00%     17.80%     17.80%     22.03%     17.37%       27. Financial planning, retirement, incorporation     29.24%     14.41%     16.53%     22.88%     16.95%       28. Personal health     23.73%     17.37%     20.34%     22.03%     15.68%       30. Endoscopy: Capsule     24.58%     17.80%     21.19%     20.76%     15.68%       31. Barrett's esophagus     13.56%     17.80%     21.19%     23.73%     14.83%       32. Endoscopy: EUS     35.59%     18.22%     19.49%     11.86%     14.83%       33. Teaching theory & techniques     19.07%     21.19%     23.73%     14.83%       34. Portal HTN and cirrhosis     20.34%     15.25%     17.80%     32.20%     14.41% <			54.7576	10.9378	10.2270	10.3978	19.4976
25. Non-reflux esophogeal disorders (eosinophilic esophagitis, etc.)     11.44%     16.95%     15.68%     38.14%     17.80%       26. Endoscopy: Advanced modalities (e.g. double balloon, PDT, etc.)     25.00%     17.80%     17.80%     22.03%     17.37%       27. Financial planning, retirement, incorporation     29.24%     14.41%     16.53%     22.88%     16.95%       28. Personal health     23.73%     17.37%     20.34%     22.03%     16.53%       29. Autoimmune liver diseases     20.76%     16.53%     19.49%     27.54%     15.68%       30. Endoscopy: Capsule     24.58%     17.80%     23.11%     30.51%     14.83%       31. Barrett's esophagus     13.56%     17.80%     23.31%     30.51%     14.83%       33. Teaching theory & techniques     19.07%     21.19%     23.73%     14.83%       34. Portal HTN and cirrhosis     20.34%     15.25%     17.80%     32.20%     14.41%       35. Ucer disease/Helicobacter/NSAIDs     13.56%     21.19%     21.61%     30.08%     13.56%       36. Reflux     15.25%     27.12%     28.81%     12.7			10.59%	19.07%	12.71%	38.56%	19.07%
(eosinophilic esophagitis, etc.)11.44%16.95%15.68%38.14%17.80%26. Endoscopy: Advanced modalities (e.g. double balloon, PDT, etc.)25.00%17.80%17.80%22.03%17.37%27. Financial planning, retirement, incorporation29.24%14.41%16.53%22.88%16.95%28. Personal health23.73%17.37%20.34%22.03%15.68%29. Autoimmune liver diseases20.76%16.53%19.49%27.54%15.68%30. Endoscopy: Capsule24.58%17.80%23.31%30.51%14.83%32. Endoscopy: EUS35.59%18.22%19.49%11.86%14.83%33. Teaching theory & techniques19.07%21.19%21.19%23.73%14.83%34. Portal HTN and cirrhosis20.34%15.25%17.80%32.20%14.41%35. Ulcer disease/Helicobacter/NSAIDs13.56%21.19%21.61%30.08%13.56%36. Reflux15.68%22.03%23.31%26.27%12.71%38. Office management32.20%14.83%18.22%22.03%12.71%38. Office management32.20%16.10%17.80%25.85%10.59%41. Viral hepatitis25.00%25.00%19.92%20.34%9.75%42. Starting a practice52.12%16.53%11.02%11.02%9.32%43. Gender issues in gastroenterology27.54%27.54%15.68%16.10%8.05%44. Closing a practice43.64%16.53%15.68%<	24.	Obesity	10.17%	17.37%	22.03%	32.20%	18.22%
double balloon, PDT, etc.)25.00%17.80%17.80%22.03%17.37%27. Financial planning, retirement, incorporation29.24%14.41%16.53%22.88%16.95%28. Personal health23.73%17.37%20.34%22.03%16.53%29. Autoimmune liver diseases20.76%16.53%19.49%27.54%15.68%30. Endoscopy: Capsule24.58%17.80%21.19%20.76%15.68%31. Barrett's esophagus13.56%17.80%23.31%30.51%14.83%32. Endoscopy: EUS35.59%18.22%19.49%11.86%14.83%33. Teaching theory & techniques19.07%21.19%23.73%14.43%34. Portal HTN and cirrhosis20.34%15.25%17.80%32.20%14.41%35. Ulcer disease/Helicobacter/NSAIDs13.56%21.19%21.61%30.08%13.56%36. Reflux15.68%22.03%23.31%26.27%12.71%37. Ethical Issues16.10%15.25%27.12%28.81%12.71%38. Office management32.20%14.83%18.22%22.03%12.71%39. Liver malignancies (HCC, cholangioCA, etc)29.66%16.10%17.80%25.85%10.59%41. Viral hepatitis25.00%25.00%19.92%20.34%9.75%42. Starting a practice52.12%16.53%11.02%11.02%9.32%43. Gender issues in gastroenterology27.54%20.76%27.54%15.25%8.90%44	25.		11.44%	16.95%	15.68%	38.14%	17.80%
double balloon, PDT, etc.)25.00%17.80%17.80%22.03%17.37%27. Financial planning, retirement, incorporation29.24%14.41%16.53%22.88%16.95%28. Personal health23.73%17.37%20.34%22.03%16.53%29. Autoimmune liver diseases20.76%16.53%19.49%27.54%15.68%30. Endoscopy: Capsule24.58%17.80%21.19%20.76%15.68%31. Barrett's esophagus13.56%17.80%23.31%30.51%14.83%32. Endoscopy: EUS35.59%18.22%19.49%11.86%14.83%33. Teaching theory & techniques19.07%21.19%23.73%14.43%34. Portal HTN and cirrhosis20.34%15.25%17.80%32.20%14.41%35. Ulcer disease/Helicobacter/NSAIDs13.56%21.19%21.61%30.08%13.56%36. Reflux15.68%22.03%23.31%26.27%12.71%37. Ethical Issues16.10%15.25%27.12%28.81%12.71%38. Office management32.20%14.83%18.22%22.03%12.71%39. Liver malignancies (HCC, cholangioCA, etc)29.66%16.10%17.80%25.85%10.59%41. Viral hepatitis25.00%25.00%19.92%20.34%9.75%42. Starting a practice52.12%16.53%11.02%11.02%9.32%43. Gender issues in gastroenterology27.54%20.76%27.54%15.25%8.90%44	26.	Endoscopy: Advanced modalities (e.g.					
incorporation29.24%14.41%16.53%22.88%16.95%28. Personal health23.73%17.37%20.34%22.03%16.53%29. Autoimmune liver diseases20.76%16.53%19.49%27.54%15.68%30. Endoscopy: Capsule24.58%17.80%21.19%20.76%15.68%31. Barrett's esophagus13.56%17.80%23.31%30.51%14.83%32. Endoscopy: EUS35.59%18.22%19.49%11.86%14.83%33. Teaching theory & techniques19.07%21.19%21.19%23.73%14.83%34. Portal HTN and cirrhosis20.34%15.25%17.80%32.20%14.41%35. Ulcer disease/Helicobacter/NSAIDs13.56%21.19%21.61%30.08%13.56%36. Reflux15.68%22.03%23.31%26.27%12.71%37. Ethical Issues16.10%15.25%27.12%28.81%12.71%38. Office management32.20%14.83%18.22%22.03%12.71%39. Liver malignancies (HCC, cholangioCA, etc)23.73%25.00%18.64%21.61%11.02%40. MOC essentials for Gastroenterologists29.66%16.10%17.80%25.85%10.59%41. Viral hepatitis25.00%25.00%19.92%20.34%9.75%42. Starting a practice52.12%16.53%11.02%11.02%43. Gender issues in gastroenterology27.54%20.76%27.54%15.25%8.90%44. Closing a practice <t< td=""><td></td><td>double balloon, PDT, etc.)</td><td>25.00%</td><td>17.80%</td><td>17.80%</td><td>22.03%</td><td>17.37%</td></t<>		double balloon, PDT, etc.)	25.00%	17.80%	17.80%	22.03%	17.37%
28. Personal health23.73%17.37%20.34%22.03%16.53%29. Autoimmune liver diseases20.76%16.53%19.49%27.54%15.68%30. Endoscopy: Capsule24.58%17.80%21.19%20.76%15.68%31. Barrett's esophagus13.56%17.80%23.31%30.51%14.83%32. Endoscopy: EUS35.59%18.22%19.49%11.86%14.83%33. Teaching theory & techniques19.07%21.19%23.73%14.83%34. Portal HTN and cirrhosis20.34%15.25%17.80%32.20%14.41%35. Ulcer disease/Helicobacter/NSAIDS13.56%21.19%21.61%30.08%13.56%36. Reflux15.68%22.03%23.31%26.27%12.71%37. Ethical Issues16.10%15.25%27.12%28.81%12.71%38. Office management32.20%14.83%18.22%22.03%12.71%39. Liver malignancies (HCC, cholangioCA, etc)23.73%25.00%18.64%21.61%11.02%41. Viral hepatitis25.00%25.00%19.92%20.34%9.75%42. Starting a practice52.12%16.53%11.02%11.02%9.32%43. Gender issues in gastroenterology27.54%20.76%27.54%15.25%8.90%44. Closing a practice43.64%16.53%15.68%16.10%8.05%45. Pediatric liver diseases49.15%24.15%11.44%8.47%6.78%	27.		20.249/	1 / / 1 0 /	16 520/	22.000/	10.050/
29. Autoimmune liver diseases20.76%16.53%19.49%27.54%15.68%30. Endoscopy: Capsule24.58%17.80%21.19%20.76%15.68%31. Barrett's esophagus13.56%17.80%23.31%30.51%14.83%32. Endoscopy: EUS35.59%18.22%19.49%11.86%14.83%33. Teaching theory & techniques19.07%21.19%21.19%23.73%14.83%34. Portal HTN and cirrhosis20.34%15.25%17.80%32.20%14.41%35. Ulcer disease/Helicobacter/NSAIDs13.56%21.19%21.61%30.08%13.56%36. Reflux15.68%22.03%23.31%26.27%12.71%37. Ethical Issues16.10%15.25%27.12%28.81%12.71%38. Office management32.20%14.83%18.22%22.03%12.71%39. Liver malignancies (HCC, cholangioCA, etc)23.73%25.00%18.64%21.61%11.02%41. Viral hepatitis25.00%25.00%19.92%20.34%9.75%42. Starting a practice52.12%16.53%11.02%11.02%9.32%43. Gender issues in gastroenterology27.54%20.76%27.54%15.25%8.90%44. Closing a practice43.64%16.53%15.68%16.10%8.05%45. Pediatric liver diseases49.15%24.15%11.44%8.47%6.78%	20	•					
30. Endoscopy: Capsule24.58%17.80%21.19%20.76%15.68%31. Barrett's esophagus13.56%17.80%23.31%30.51%14.83%32. Endoscopy: EUS35.59%18.22%19.49%11.86%14.83%33. Teaching theory & techniques19.07%21.19%21.19%23.73%14.83%34. Portal HTN and cirrhosis20.34%15.25%17.80%32.20%14.41%35. Ulcer disease/Helicobacter/NSAIDs13.56%21.19%21.61%30.08%13.56%36. Reflux15.68%22.03%23.31%26.27%12.71%37. Ethical Issues16.10%15.25%27.12%28.81%12.71%38. Office management32.20%14.83%18.22%22.03%12.71%39. Liver malignancies (HCC, cholangioCA, etc)29.66%16.10%17.80%25.85%10.59%41. Viral hepatitis25.00%25.00%19.92%20.34%9.75%42. Starting a practice52.12%16.53%11.02%9.32%43. Gender issues in gastroenterology27.54%20.76%27.54%15.25%8.90%44. Closing a practice43.64%16.53%15.68%16.10%8.05%45. Pediatric liver diseases49.15%24.15%11.44%8.47%6.78%							
31. Barrett's esophagus13.56%17.80%23.31%30.51%14.83%32. Endoscopy: EUS35.59%18.22%19.49%11.86%14.83%33. Teaching theory & techniques19.07%21.19%21.19%23.73%14.83%34. Portal HTN and cirrhosis20.34%15.25%17.80%32.20%14.41%35. Ulcer disease/Helicobacter/NSAIDs13.56%21.19%21.61%30.08%13.56%36. Reflux15.68%22.03%23.31%26.27%12.71%37. Ethical Issues16.10%15.25%27.12%28.81%12.71%38. Office management32.20%14.83%18.22%22.03%12.71%39. Liver malignancies (HCC, cholangioCA, etc)23.73%25.00%18.64%21.61%11.02%40. MOC essentials for Gastroenterologists29.66%16.10%17.80%25.85%10.59%41. Viral hepatitis25.00%25.00%19.92%20.34%9.75%42. Starting a practice52.12%16.53%11.02%11.02%9.32%43. Gender issues in gastroenterology27.54%20.76%27.54%15.25%8.90%44. Closing a practice43.64%16.53%15.68%16.10%8.05%45. Pediatric liver diseases49.15%24.15%11.44%8.47%6.78%							
32. Endoscopy: EUS35.59%18.22%19.49%11.86%14.83%33. Teaching theory & techniques19.07%21.19%21.19%23.73%14.83%34. Portal HTN and cirrhosis20.34%15.25%17.80%32.20%14.41%35. Ulcer disease/Helicobacter/NSAIDs13.56%21.19%21.61%30.08%13.56%36. Reflux15.68%22.03%23.31%26.27%12.71%37. Ethical Issues16.10%15.25%27.12%28.81%12.71%38. Office management32.20%14.83%18.22%22.03%12.71%39. Liver malignancies (HCC, cholangioCA, etc)23.73%25.00%18.64%21.61%11.02%40. MOC essentials for Gastroenterologists29.66%16.10%17.80%25.85%10.59%41. Viral hepatitis25.00%25.00%19.92%20.34%9.75%42. Starting a practice52.12%16.53%11.02%11.02%43. Gender issues in gastroenterology27.54%20.76%27.54%15.25%8.90%44. Closing a practice43.64%16.53%15.68%16.10%8.05%45. Pediatric liver diseases49.15%24.15%11.44%8.47%6.78%							
33. Teaching theory & techniques19.07%21.19%21.19%23.73%14.83%34. Portal HTN and cirrhosis20.34%15.25%17.80%32.20%14.41%35. Ulcer disease/Helicobacter/NSAIDs13.56%21.19%21.61%30.08%13.56%36. Reflux15.68%22.03%23.31%26.27%12.71%37. Ethical Issues16.10%15.25%27.12%28.81%12.71%38. Office management32.20%14.83%18.22%22.03%12.71%39. Liver malignancies (HCC, cholangioCA, etc)23.73%25.00%18.64%21.61%11.02%40. MOC essentials for Gastroenterologists29.66%16.10%17.80%25.85%10.59%41. Viral hepatitis25.00%25.00%19.92%20.34%9.75%42. Starting a practice52.12%16.53%11.02%11.02%9.32%43. Gender issues in gastroenterology27.54%20.76%27.54%15.25%8.90%44. Closing a practice43.64%16.53%15.68%16.10%8.05%45. Pediatric liver diseases49.15%24.15%11.44%8.47%6.78%							
34. Portal HTN and cirrhosis20.34%15.25%17.80%32.20%14.41%35. Ulcer disease/Helicobacter/NSAIDs13.56%21.19%21.61%30.08%13.56%36. Reflux15.68%22.03%23.31%26.27%12.71%37. Ethical Issues16.10%15.25%27.12%28.81%12.71%38. Office management32.20%14.83%18.22%22.03%12.71%39. Liver malignancies (HCC, cholangioCA, etc)23.73%25.00%18.64%21.61%11.02%40. MOC essentials for Gastroenterologists29.66%16.10%17.80%25.85%10.59%41. Viral hepatitis25.00%25.00%19.92%20.34%9.75%42. Starting a practice52.12%16.53%11.02%11.02%9.32%43. Gender issues in gastroenterology27.54%20.76%27.54%15.25%8.90%44. Closing a practice43.64%16.53%15.68%16.10%8.05%45. Pediatric liver diseases49.15%24.15%11.44%8.47%6.78%							
35. Ulcer disease/Helicobacter/NSAIDs13.56%21.19%21.61%30.08%13.56%36. Reflux15.68%22.03%23.31%26.27%12.71%37. Ethical Issues16.10%15.25%27.12%28.81%12.71%38. Office management32.20%14.83%18.22%22.03%12.71%39. Liver malignancies (HCC, cholangioCA, etc)23.73%25.00%18.64%21.61%11.02%40. MOC essentials for Gastroenterologists29.66%16.10%17.80%25.85%10.59%41. Viral hepatitis25.00%25.00%19.92%20.34%9.75%42. Starting a practice52.12%16.53%11.02%11.02%43. Gender issues in gastroenterology27.54%20.76%27.54%15.25%8.90%44. Closing a practice43.64%16.53%15.68%16.10%8.05%45. Pediatric liver diseases49.15%24.15%11.44%8.47%6.78%							
36. Reflux15.68%22.03%23.31%26.27%12.71%37. Ethical Issues16.10%15.25%27.12%28.81%12.71%38. Office management32.20%14.83%18.22%22.03%12.71%39. Liver malignancies (HCC, cholangioCA, etc)23.73%25.00%18.64%21.61%11.02%40. MOC essentials for Gastroenterologists29.66%16.10%17.80%25.85%10.59%41. Viral hepatitis25.00%25.00%19.92%20.34%9.75%42. Starting a practice52.12%16.53%11.02%11.02%43. Gender issues in gastroenterology27.54%20.76%27.54%15.25%8.90%44. Closing a practice43.64%16.53%15.68%16.10%8.05%45. Pediatric liver diseases49.15%24.15%11.44%8.47%6.78%							
37. Ethical Issues16.10%15.25%27.12%28.81%12.71%38. Office management 39. Liver malignancies (HCC, cholangioCA, etc)32.20%14.83%18.22%22.03%12.71%40. MOC essentials for Gastroenterologists23.73%25.00%18.64%21.61%11.02%41. Viral hepatitis29.66%16.10%17.80%25.85%10.59%42. Starting a practice52.12%16.53%11.02%11.02%43. Gender issues in gastroenterology27.54%20.76%27.54%15.25%8.90%44. Closing a practice43.64%16.53%15.68%16.10%8.05%45. Pediatric liver diseases49.15%24.15%11.44%8.47%6.78%							
38. Office management 39. Liver malignancies (HCC, cholangioCA, etc)32.20%14.83%18.22%22.03%12.71%39. Liver malignancies (HCC, cholangioCA, etc)23.73%25.00%18.64%21.61%11.02%40. MOC essentials for Gastroenterologists29.66%16.10%17.80%25.85%10.59%41. Viral hepatitis25.00%25.00%19.92%20.34%9.75%42. Starting a practice52.12%16.53%11.02%11.02%43. Gender issues in gastroenterology27.54%20.76%27.54%15.25%8.90%44. Closing a practice43.64%16.53%15.68%16.10%8.05%45. Pediatric liver diseases49.15%24.15%11.44%8.47%6.78%							
39. Liver malignancies (HCC, cholangioCA, etc)23.73%25.00%18.64%21.61%11.02%40. MOC essentials for Gastroenterologists29.66%16.10%17.80%25.85%10.59%41. Viral hepatitis25.00%25.00%19.92%20.34%9.75%42. Starting a practice52.12%16.53%11.02%11.02%43. Gender issues in gastroenterology27.54%20.76%27.54%15.25%8.90%44. Closing a practice43.64%16.53%15.68%16.10%8.05%45. Pediatric liver diseases49.15%24.15%11.44%8.47%6.78%							
cholangioCA, etc)23.73%25.00%18.64%21.61%11.02%40. MOC essentials for Gastroenterologists29.66%16.10%17.80%25.85%10.59%41. Viral hepatitis25.00%25.00%19.92%20.34%9.75%42. Starting a practice52.12%16.53%11.02%11.02%9.32%43. Gender issues in gastroenterology27.54%20.76%27.54%15.25%8.90%44. Closing a practice43.64%16.53%15.68%16.10%8.05%45. Pediatric liver diseases49.15%24.15%11.44%8.47%6.78%			32.20%	14.83%	18.22%	22.03%	12.71%
40. MOC essentials for Gastroenterologists29.66%16.10%17.80%25.85%10.59%41. Viral hepatitis25.00%25.00%19.92%20.34%9.75%42. Starting a practice52.12%16.53%11.02%11.02%9.32%43. Gender issues in gastroenterology27.54%20.76%27.54%15.25%8.90%44. Closing a practice43.64%16.53%15.68%16.10%8.05%45. Pediatric liver diseases49.15%24.15%11.44%8.47%6.78%	55.		23.73%	25.00%	18.64%	21.61%	11.02%
41. Viral hepatitis25.00%25.00%19.92%20.34%9.75%42. Starting a practice52.12%16.53%11.02%11.02%9.32%43. Gender issues in gastroenterology27.54%20.76%27.54%15.25%8.90%44. Closing a practice43.64%16.53%15.68%16.10%8.05%45. Pediatric liver diseases49.15%24.15%11.44%8.47%6.78%	40.	MOC essentials for					
42. Starting a practice52.12%16.53%11.02%9.32%43. Gender issues in gastroenterology27.54%20.76%27.54%15.25%8.90%44. Closing a practice43.64%16.53%15.68%16.10%8.05%45. Pediatric liver diseases49.15%24.15%11.44%8.47%6.78%		•					
43. Gender issues in gastroenterology27.54%20.76%27.54%15.25%8.90%44. Closing a practice43.64%16.53%15.68%16.10%8.05%45. Pediatric liver diseases49.15%24.15%11.44%8.47%6.78%							
44. Closing a practice43.64%16.53%15.68%16.10%8.05%45. Pediatric liver diseases49.15%24.15%11.44%8.47%6.78%		• •					
45. Pediatric liver diseases 49.15% 24.15% 11.44% 8.47% 6.78%		• • •					
		•					
46. CanMEDS: Professional     35.17%     15.68%     20.76%     22.46%     5.93%							
	46.	CanMEDS: Protessional	35.17%	15.68%	20.76%	22.46%	5.93%



#### Q15 What is your preferred method of learning (check all that apply)?



## 9 DDW

#### **Executive Summary of CAG CPD Strengths and Weaknesses**

CAG CPD Strengths include:

- Broad range of educational opportunities
- Well-organized
- Leader in CPD
- SEE™, CDDW™, CPGs and ePortal are all valued

CAG CPD Weaknesses include:

- Luminal GI and hepatology groups should be reintegrated
- Not enough basic science content
- Recurring topics and speakers
- CPGs and CAG programs are not well advertised or promoted

(For ALL comments regarding Strengths and Weaknesses, please refer to APPENDIX B and C)



## APPENDIX A Q12 OTHER topics that you would like to see covered

360 Evaluation Access to care Acute liver failure	Ending a physician-patient relationship Enterocyte functions enteroendocrine
Advanced resection techniques for early GI neoplasia	Epigenetics -role in GI disease
Advice for residents interested in starting a	epithelial interactions in GI disease - The rôle of mesenchymal
research career Ancient GI microbiome	ESD
Animal models to study IBD	ESD
antibiotic resistance	Ethics/Integrity of practice: doing procedures for money and very little else. How can we control this?
anticoagulation management	EUS therapeutics
Approach to functional disorders, ie pyschological support	Exercise and Cancer
approach to/advanced treatments for fecal incontinence	Exercise and GIT
Asking research questions in clinical practice autoantibodies Autonomic control of GI functions Billing efficiency Biological in IBD biomarkers in IBD	Familial risk of pancreatic cancer - who, when & how to screen Fatty liver post-liver transplant fecal microbial transplantation Fecal microbiota transplant Feedback fibrosis and intestinal remodelling in IBD
CAG approved standardized informed	FMT review of future potential
consent for endoscopic procedures:what MUST be said and documented Cancer Caring of the liver transplant patient Cognitive behavioural therapy in gastroenterology	Function and mechanisms of cannabinoids in IBD + IBS Gastric cancer treatment surg/med gastrovascular abnormality
Colorectal cancer screening	genetics
Competence by Design - need to include this - GI is on list for this in 2019	GI toxicology
Competency based medical education	GI tract microscopy
CRC screening at a population level	GI Tract related pain
Current treatment for Gi cancers we diagnose	Gut-Brain Axis
Dealing with clinical situations which don't fit the guidelines	Gut-brain axis
Diet and inflammation	health services utilization
Doctor wellbeing and health	Helicobacter pylori mechanism of pathogenesis

## APPENDIX A OTHER Topics continued

Herbs and spices in IBD and IBS	Metatranscriptomics of IBD microbiome and colorectal cancer/polyps
Hereditary cancer syndromes high resolution manometry How to educate referring physicians who send their patients for QUICK scopes before they refer to you for a clinical answer	mitochondria and disease MRI and motility
How to protect the patient - implementation of procedural training competency across specialities/subspecialities	mucosal responses to stress and injury
Ibd ibd dysplasia/colitis-associated neoplasm Immune cell-microbiota cross-talk Immunometabolism in IBD	multichannel intraluminal impedance-pH monitoring NAFLD Necrotizing enterocolitis Neuoendocrine tumors
Infections in IBD - CMV and CDI	Neuroendocrine tumours epidemiology, diagnosis, mgmt
Innate host defenses innate lymphoid cells Intestinal epithelium	Neuro-Immune interactions Neuromodulation of GI disorders
Intestinal growth	New concepts in epithelial barrier and repair New experimental approaches - organoids, imaging, molecular biology ("omics")
investigator initiated clinical trials Involvement of the enteric nervous system in GI diseases	New surgical techniques for GI Non-celiac gluten/wheat sensitivity
legal responsibilities dealing with difficult patients	Non-opioid pain management
Liver transplant & alcohol	NSAID induced disease of GI
Lower hi bleed	Nutrient sensing by the gut
Management of chronic abdominal pain Management of chronic nausea Management of IBS	Obesity Pain management in severe IBS paliative care in end of life GI disorders
Maternal Health and GI Disease (i.e. IBD) Management of chronic abdominal pain	pancreatic cancer Pathobionts in IBD
Management of chronic nausea Management of IBS	pathogenesis of pancreatic cancer Pediatric and Transition Care
Maternal Health and GI Disease (i.e. IBD)	pediatric liver transplant
mechanisms of action of antibody-based biologics	Perianal Crohn's disease
mechanisms of disease in peptic ulcers Mechanisms of NASH	Physician burnout Physicians with disabilities (burnout, damage/pain from doing procedures, where and who to give support and options without a union to support us, etc
Metabolomics of IBD	

#### APPENDIX A OTHER Topics continued

Politicians - why they put down health care and MDs

Positioning of Biologics in IBD

PREGANCY AND LIVER DISEASE

PREGNACY AND IBD

psychiatric comorbidities in chronic GI diseases

Quality improvement in colonsocopy, colon cancer screening and increasing ADR

Radiation treatment and GSi disease

Refractory Ascites/ Peritoneo-vesical shunt

Refractory Celiac disease

signaling in GI cancer

Stem cell biology

stem cells

Stem cells in the gut and potential therapies

Tansition of care in IBD

Teaching endosscopy

Techniques of colonoscopy

Technology in patient management and communication

The role of gastroenterologist in the management of Parkinson's (as a symposium)

Therapeutic applications of EUS

Therapeutic endoscopy

Time management

TPN related topics

Ultrasound and motility

Workup/management of chronic abdominal pain

#### **APPENDIX B**

## Q17 Please comment on a strength of the CAG's CPD activities

Answered: 61 Skipped: 188

#	RESPONSES
1	SEE program is excellent
2	Excellent speakers brought in from other countries.
3	Practical, particularly with hand-on courses and CAG reviews of major meetings
4	There are regular updates.
5	Last CDDW was below average
6	Clinically relevant.
7	No Comment
8	It is an Evolving Process
9	CAG seeks out the best educators in Canada, and this helps foster excellent programs.
10	na
11	As a basic science researched, I do not require CPD credits but the sessions I did attend gave me greater understanding into the challenges physicians see in the clinic.
12	Well organized
13	The GI topics leading up to CDDW is a great way to discuss your research as well as others and creates collaboration.
14	N/A
15	Informative activities Good organization
16	Quality, enthousiasm
17	Provides a number of different options
18	Usually well organized and focused and not too long -
19	Evidence based. Well planned
20	N/A
21	Available on line, somewhat easy to watch and learn
22	Having only attended CDDW my commentary is limited, but it was a very comprehensive, engaging, and fun conference that I look forward to attending year after year!
23	Well organized, quality, without bias.
24	Quality of CDDW very good
25	Up to date, information reliable, opportunity to network with other GIs impt for me in small center
26	CAG's CPD activities are truly outstanding
27	SEE program was very educational and enlightening. I recommend it to all my colleagues
28	Being able to watch things online at a convenient time.
29	Continuously revisited to ensure alignment with the CAG members' goals.
30	Well organized. Accessible.
31	CAG has been a leader in CPD development in Canada.
32	A few good events for basic science trainees (eg Gi topics, CDDW)

## APPENDIX B

## Strengths of CAG CPD Activities continued

33	Broad range of educational opportunities meeting multiple sections of MOC requirements and my personal needs
34	What is provided was good
35	Various options for learning re: on-line, self-assessment, conference, etc
36	Easily available
37	wide variety of opportunities using different modalities
38	diverse, comprehensive CDDW programming
39	Hands on courses
40	The online CME on the website is great. As section 3 credits are hard to obtain, any further programs would be great
41	Nothing strikes me
42	I make a point to go to CDDW on an annual basis ( this one in 2018 was missed only because of health reasons as I was rear ended in a car accident) because it allows me the best way to see colleagues (I am a solo practitioner in the community) and to see what devices are available at present and in the near future. I also go to as many lectures as I can as it is a great deal of information in one spot.
43	N/A
44	No comment as I have not used them.
45	good overall menu
46	Overall, very well organized.
47 48	Inclusive. Easy digital access Innovative. Self assessment programs are both effective and very helpful for MOCOMP.
49	The consensus statements over the last few years have all been excellent
50	Consistency
51	I strongly enjoyed going to CDDW as a Master's student, the lectures were quite informative.
52	Evidence based
52	Well done
53	The online portal is easy to access and use
54	CDDW was very informative
55	Significantly influenced my understanding and practice
56	CDDW very well organized and executed
57	One of the most developed CPD accreditation programs in Canada
58	SEE is a very well run program
59	1
60	I am new to CAG and very much like and support their mission.
61	

#### APPENDIX C

#

1

2

3

4

5 6

7

8 9

10

11

12

13 14

15

16

17

18 19

20 21

22

23

24

25

26

27

28

Mostly geared towards gastroenterologist.

#### Q18 Please comment on a weakness of the CAG's CPD activities

Answered: 58 Skipped: 191 RESPONSES Location of meeting in Banff is an obstacle to attendance even for physicians in Western Canada Must improve poster sessions. not at the end of the day. Ask for posters to up all day There is little opportunity for larger involvement in learning activities (i.e. with the development of programs, or learning materials). The goal of learning is to also teach. These opportunities are limited to few individuals. The website is old and difficult to navigate. CDDW is organized in cities such as Banff that are often difficult to reach. Why not Vancouver or other cities where you can just fly ? Some CAG guidelines are extremely old and is no longer applicable in clinical practice. We need updated guidelines in many areas, to name a few: IBD, IBS management, etc. Need to re-integrate luminal GI and hepatoloogy groups in the the annual CDDW No Comment None, This is an evolving Process Not enough focus on specialty endoscopy (EUS/ERCP etc.) na Many of the CPD activities and sessions (at CDDW 2018) were directed toward residents and physicians. There was only a single basic science CPD session (intestinal fibrosis) and it would be of benefit to include more basic science CPD sessions. Provide training sessions for basic scientists on different topics Not enough basic science at CDDW, too many clinical talks. N/A None Activities seem somewhat weighted according to industry inputs - eg what 'mab are we trying out today? over: what's new in potential cheap IBD management, such as worms and other earthy possibilities? Need more accredited self learning modules Insufficient pediatric content/focus N/A More interactive activities Intermittent, traditional (non-innovative), sometimes repetitive but this is improving. Wish there were more opportunities, or perhaps mini conferences in each province Last CDDW spent too much time on paediatrics. I missed having CASL as part of it No weaknesses identified I don't know if it's just me but I wish the resource online were maybe a bit easier to access. Eg. apps or podcasts. There is an opportunity to develop interactive clinical education activities. Split from CASL is a BIG WEAKNESS. Need to get back together - not a good message to trainees. Input from the 'silent' non-participants - what can CAG do to engage them?

#### **APPENDIX C** Weaknesses of CAG CPD Activities continued

29	None noted
30	Cddw small talk sessions are organized in the manner that interesting topics occur in the same time and cannot be attended. Big lectures are less educational then small group topucs
31	need more awareness of on-line CPD activities
32	Not engaged by all gastroenterologist . Hepatology not engaged
33	Hard to serve pediatric as well as adult GIs
34	Advertising their CPD activities to the GI community at large. Also, CDDW needs to feature topics more relevant to daily clinical GI practice. I find it is mostly geared towards diversifying the educational experience of GI fellows, or at times, too heavy on the basic sciences. As a busy practicing GI in a community and teaching facility, I strive to get a general review of most areas in GI when I attend a conference for a few days. The topics typically presented each year I find are more concentrated on the interests of the conference organizers or the keynote visiting professors. If CDDW featured an AGA postgrad type course review, there would be much more attendees faithfully attending the conference yearly.
35	I was very disappointed in cddw this year. The divorce from CASL has to be resolved as the majority of liver care in this country outside of only a few major centres is still provided by GI. The over representation of pediatric issues was a poor substitute. I will not attend in future if this continues in the future
36	not promoted as a mission
37	Same themes in meetings with same speakers
38	Focus has shifted way too much on IBD and biologics.
39	Unless one is in academia or on a board at CAG, one can tend to forget all the guidelines that CAG has, for eg., and reach out to other avenues like "Up to Date". They are not advertised well when they come on line.
40	N/A
41	No comments
42	there are recurring themes that are not of particular interest
43	None
44	Engagement of members.
45	Would like even more practice audit/self assessment programs
46	More research-oriented lectures at CDDW?
47	Faculty too often the same
48	not enough informations
49	The guideline library is very poorly organized and difficult to navigate. Dividing the topics into upper GI and lower GI is too broad. It should be broken up into more specific categories such as IBD, colon cancer screening, etc.
50	too extensive
51	Expensive accommodation
52	Other activities perhaps less emphasized and advertized
53	More cutting edge topics (artificial intelligence, eHealth, future of clinician-researchers) and less CME reviews
54	Lack of coordination with CASL
55	Only attended SEE, and no obvious weakness.
56	I
57 58	No weaknesses note so far.